Home/Libra Therapeutics/Martin Gill, PhD

MG

Martin Gill, PhD

Chief Scientific Officer

Libra Therapeutics

Therapeutic Areas

Neurodegenerative Diseases Amyotrophic Lateral Sclerosis Frontotemporal Dementia Alzheimer's Disease Parkinson's Disease Huntington's Disease

Libra Therapeutics Pipeline

Drug	Indication	Phase
Lysofunction Platform / TRPML1	Neurodegenerative Diseases (ALS, PD, etc.)	Preclinical
C9orf72 RAN Translation Inhibition	C9orf72-associated ALS/FTD	Discovery
C9orf72 Transcriptional Modification	C9orf72-associated ALS/FTD	Discovery
Undisclosed Target	Not Disclosed	Discovery

Leadership Team at Libra Therapeutics

Shawn Scranton, PharmD

Chief Executive Officer & President

Gene Kinney, PhD

Chairman of the Board

View full Libra Therapeutics profile